Moshik Cohen Kutner, PhD

CEO
Omnix Medical Ltd., Israel

Disclosure(s): No financial relationships to disclose

Poster(s):

• (P-109) A Phase I First-in-Human Study to Evaluate the Safety and Pharmacokinetic (PK) Properties of the Intravenously (IV) Administered OMN6, A Novel Antimicrobial Peptide Targeting Acinetobacter baumannii (AB), in Adults including Older Healthy Volunteers (HVs) Subjects
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT